Our Mission

The primary mission of the Pediatric Early Phase-Clinical Trial Network (PEP-CTN) is to identify and develop effective new agents for children and adolescents with cancer through rational and efficient clinical and laboratory research.

PEP-CTN clinical trials will incorporate correlative genomic, biology, pharmacology, and imaging studies to further the understanding of the disposition and action of new agents introduced into the treatment of children with cancer.